Through integrative analysis of the Cancer Genome Atlas (TCGA)-LIHC database, two expression profiles for HCC and normal tissues (GSE19665 and GSE202853) and an expression profile for lenvatinib-resistant HCC cells (GSE186191), we identified three genes, including FAM111B, RRAGD, and AKR1C1, as potential targets for HCC treatment. Here, FAM111B is linked to hepatocellular carcinoma.